Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 19, 2004New England Journal of Medicine

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

View Full Paper
Ask AI
Bookmark
Share

Authors

TLThomas J. LynchNationwide Children's HospitalDBDaphne W. BellNational Institutes of HealthRSRaffaella SordellaCold Spring Harbor Laboratory

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lynch et al. (2004) studied this question.

synapsesocial.com/papers/69daaab7a6045d71bfa3dafchttps://doi.org/10.1056/nejmoa040938
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial2002 · 579 citations
  2. 2Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer2002 · 5,008 citations
  3. 3Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor2003 · 2,319 citations